Zhao et al. showed that metabolomic profiling could distinguish low- and high-grade gliomas with 91.1% accuracy using a panel of 18 metabolites and differentiate IDH-mutated from IDH wild-type patients through six specific metabolites. This evidence concerns the gene IDH1 and central nervous system cancer.